ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1122

Clinical Realities in Patients with Adult Onset Still’s Disease: Real-World Diagnosis and Management

Chloe Heiting1, Karen Gambina2 and Bella Mehta3, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medical College, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Biomarkers, classification criteria, Diagnostic criteria, Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Adult Onset Still’s Disease (AOSD) is a rare systemic inflammatory disorder characterized by inflammatory polyarthritis, daily fever, and a transient salmon-pink maculopapular rash. Diagnosis of AOSD is challenging as patients may have a variety of non-specific symptoms and laboratory abnormalities, and diagnosis is often exclusionary due to the ambiguous nature of its presenting symptoms. Interleukin 18 (IL-18) levels have been found to be markedly elevated in AOSD patients,1 and present a promising indicator for disease activity and diagnosis. We aimed to describe a cohort of AOSD patients, including their serum IL-18 levels and treating rheumatologist-reported disease activity, as seen in outpatient clinic visits at a tertiary care referral hospital in the United States.

Methods: We enrolled adult patients (≥18 years) with AOSD in a prospective cohort. Patients were identified by ICD-10 codes (M06.1). Clinical diagnosis of AOSD was then confirmed with the patients’ respective treating rheumatologists, and subsequently via chart review by a second rheumatologist who oversees a specialized AOSD practice. Patients with a different disease that explained the clinical picture better than AOSD were excluded. Demographic data, medication use, medical history, and laboratory results were collected via chart review. Patients were characterized using three standard AOSD diagnostic criteria – Yamaguchi, Cush, Fautrel – and descriptive statistics were reported.

Results: 39 patients were enrolled, majority White (59.0%) and female (74.4%) (Table 1). Of the examined diagnostic criteria, only 30.8% of patients met all three and 20.5% fit none (Figure 1). All patients were treated clinically as AOSD despite differences in fulfilling diagnostic criteria.

23.6% of patients had a history of macrophage activation syndrome (MAS). Peak ferritin levels were markedly elevated in the cohort (median 2102.5 ng/mL, IQR [445, 10798], n=38). 12 patients presented with elevated peak ferritin levels >10,000 ng/mL, including 6 with history of MAS.

Serum IL-18 levels were measured in 7 patients (median 554 pg/mL, IQR [246.5, 36151]), and were elevated in 4 patients whose treating rheumatologists noted worsening of clinical symptoms at time of measurement.

Conclusion: We characterized a cohort treated clinically as AOSD and identified that 20.5% did not fit any diagnostic criteria while only 30.8% met all three. It is imperative to recognize that not all patients neatly fit into established criteria, and patients may be excluded depending on which criteria was selected, highlighting the heterogeneity of the disease. Serum IL-18 levels were only measured in a portion of our cohort, but we observed an association between elevated serum IL-18 levels and worsening symptoms as noted by the treating rheumatologist. Continued disease characterization and measurement of serum IL-18 levels in AOSD patients, especially to further elucidate its potential role in AOSD diagnosis, is necessary in rare diseases where traditional diagnostic criteria may not be the clinical reality.

1. Colafrancesco et al. IL-18 Serum Level in Adult Onset Still’s Disease: A Marker of Disease Activity. PMID: 22762008.

Supporting image 1

Table 1. Cohort demographics and clinical characteristics

Supporting image 2

Figure 1. Cohort fulfillment of Yamaguchi Criteria, Cush Criteria, and Fautrel Criteria (n=39)


Disclosures: C. Heiting: None; K. Gambina: None; B. Mehta: None.

To cite this abstract in AMA style:

Heiting C, Gambina K, Mehta B. Clinical Realities in Patients with Adult Onset Still’s Disease: Real-World Diagnosis and Management [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinical-realities-in-patients-with-adult-onset-stills-disease-real-world-diagnosis-and-management/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-realities-in-patients-with-adult-onset-stills-disease-real-world-diagnosis-and-management/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology